AccessibilityHelpAbout Us
AdAlta logo

AdAlta(ASX) 1AD

Market CapA$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-99%
5 Year-96%
1 Year+0%
1 Month+0%
A$0.00
+0.00%
+0.00Today
AdAlta last closing stock price
MetricPriceDate
Last closeAUD 0.002026-09-07
AdAlta stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.002026-08-31
1 month+0%AUD 0.002026-08-07
3 month+0%AUD 0.002026-06-09
Year to date+0%AUD 0.002025-12-31
1 year+0%AUD 0.002025-09-04
3 year-78.99%AUD 0.012023-09-08
5 year-96.43%AUD 0.082021-09-08
Since inception-98.64%AUD 0.222016-08-22

AdAlta Financials at a Glance

Market Cap

A$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$677.01K

Net Income (TTM)

-A$9.19M

EPS (TTM)

-A$0.00

P/E Ratio

-1.30

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.00

Volume

2,016,962

Open

A$0.00

Previous Close

A$0.00

Daily Range

A$0.00 - A$0.00

52-Week Range

A$0.00 - A$0.01

Estimated Earnings Date

Feb 25, 2027

1AD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AdAlta

AdAlta Limited is an Australian-based clinical-stage biotechnology company focused on developing innovative protein therapeutics. The company is advancing its lead investigational drug candidate, AD-214, which is currently in Phase I clinical trials for idiopathic pulmonary fibrosis and related fibrotic diseases.

Products and Services
  • AD-214: Investigational drug for idiopathic pulmonary fibrosis
  • Strategic alliances for i-body development with GE Healthcare
  • Partnership with Carina Biotech for CAR-T cell products
Growth Outlook
  • AD-214 is progressing through Phase I trials, indicating potential market entry
  • Collaborations with industry leaders enhance research capabilities
  • Focus on expanding therapeutic applications for i-bodies
Financial Highlights
  • Recent quarterly revenue of AUD 0, reflecting ongoing R&D investment
  • Trailing twelve months (TTM) net income loss of AUD 9.5 million
  • Cash and cash equivalents of AUD 1.28 million as of June 30, 2026
AdAlta Limited operates in the biotechnology sector, emphasizing the development of unique therapeutic solutions. The company’s lead candidate, AD-214, is positioned to address significant unmet medical needs in fibrotic diseases. With strategic partnerships and a focus on innovative protein therapeutics, AdAlta is well-placed to leverage its research capabilities for future growth. The financial data indicates a commitment to research and development, although the company is currently operating at a loss. Investors may find interest in the potential of AdAlta's pipeline and its strategic collaborations, which could enhance its market position in the biotechnology landscape.
AI Generated • Aug 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Timothy Oldham, PhD

Website

www.adalta.com.au

Headquarters

Camberwell, VIC 3124, AU

1AD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-6182.61%

Return on Capital

-1296.92%

Return on Assets

-272.07%

Earnings Yield

-76.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.21B

Volume

2.02M

Avg. Volume

1.62M

Financials (TTM)

Gross Profit

A$457.50K

Operating Income

-A$9.18M

EBITDA

-A$9.18M

Operating Cash Flow

-A$7.38M

Capital Expenditure

A$2.00

Free Cash Flow

-A$7.38M

Cash & ST Invst.

A$1.28M

Total Debt

A$0.00

AdAlta Performance Analysis

AdAlta annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
AdAlta sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-37.3%
Q42025-06-30-19.5%
Q22025-12-31-100.0%
Q42026-06-30N/A
AdAlta annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-30.1%
20242024-06-30AUD -0.01-28.9%
20252025-06-30AUD -0.01-24.2%
20262026-06-30AUD -0.00-66.7%
AdAlta sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-314.5%
Q42025-06-3033.3%
Q22025-12-3188.6%
Q42026-06-3056.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

A$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

A$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$4.82M

N/A

Employees

2

N/A

Net Income

-A$2.25M

+5.1%

EBITDA

-A$2.31M

+2.6%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$1.28M

-59.0%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$273.60K

-84.9%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$0.00

-100.0%

Return on Assets

-2.72%

N/A

Return on Invested Capital

-12.97%

N/A

Free Cash Flow

-A$3.95M

-33.6%

Operating Cash Flow

-A$3.95M

-33.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZLD.AXZelira Therapeutics Limited
A$0.50+0.00%
ACR.AXAcrux Limited
A$0.01+0.00%
IBX.AXImagion Biosystems Limited
A$0.01-5.88%
EXL.AXElixinol Wellness Limited
A$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.47+0.09%
NVDANvidia
$225.73-0.02%
ATAIAtaiBeckley
$7.28-0.01%
NOKNokia
$10.65+0.06%

Questions About 1AD

What is the current price of AdAlta?

AdAlta is trading at A$0.00 per share.

What is the 52-week range for AdAlta?

Over the past 52 weeks, AdAlta has traded between A$0.00 and A$0.01.

How much debt does AdAlta have?

As of the most recent reporting period, AdAlta reported total debt of A$0.00.

How much cash does AdAlta have on hand?

AdAlta reported A$1.28M in cash and cash equivalents in its most recent financial results.

What is AdAlta’s dividend yield?

AdAlta does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services